Clinicians globally must understand the risks of Andes virus infection because of its unique person-to-person transmission. Therefore, medical authorities in India have increased surveillance to monitor potential cases. Consequently, doctors should recognize the clinical features of this severe disease. Fortunately, early intervention can significantly improve patient outcomes.
Clinical Features of Andes Virus Infection
Typically, the incubation period lasts between one and six weeks. Patients initially present with non-specific symptoms such as fever, muscle aches, and headache. Additionally, some individuals experience abdominal pain, vomiting, and diarrhea. Consequently, clinicians often confuse these symptoms with other common tropical infections. However, the disease can rapidly progress to a cardiopulmonary phase characterized by severe respiratory distress. This phase leads to shock and pulmonary edema, which carry a high mortality rate.
Clinical Management and Treatment Options
Currently, supportive care remains the cornerstone of clinical management for infected patients. Specifically, doctors must maintain fluid balance and provide mechanical ventilation when necessary. In addition, experimental therapies are undergoing active research. Researchers are evaluating ribavirin and other antiviral agents in clinical trials. Furthermore, emerging monoclonal antibody therapies offer promising options to target the virus directly. Ultimately, clinicians must implement strict isolation protocols to prevent hospital-based transmission.
Infection Prevention and Indian Surveillance
Recently, the Indian Health Ministry activated nationwide surveillance networks to track potential hantavirus cases. Therefore, hospitals must report suspected infections immediately to local health officials. Additionally, staff should use personal protective equipment when handling high-risk patients. Because this pathogen spreads through close contact, strict hand hygiene is vital. Moreover, proper rodent control remains the most effective long-term preventive strategy. Through these joint efforts, healthcare systems can successfully mitigate outbreak risks.
Frequently Asked Questions
Q1: Can Andes virus infection spread between humans?
Yes. This pathogen is the only hantavirus with documented person-to-person transmission, which usually occurs through close and prolonged contact.
Q2: Is there an approved vaccine for this disease?
Currently, no widely available vaccine exists. However, researchers are actively developing and testing several investigational vaccine candidates.
Q3: How does India monitor this virus?
Recently, India deployed a robust laboratory network to track and screen potential cases following international outbreaks.
References
- Harris GH et al. Andes Virus – A Clinical Review. N Engl J Med. 2026 Jul 15. doi: 10.1056/NEJMra2606651. PMID: 42456129.
- World Health Organization. Hantavirus cluster linked to cruise ship travel, Multi-country. WHO Disease Outbreak News. 2026 May 8.
- NDTV. Hantavirus Surveillance: India Deploys 165-Lab ‘Viral Shield’ To Track Virus Spread. NDTV News. 2026 May 11.